Founders Capital Management Sells 90 Shares of Johnson & Johnson (JNJ)

Founders Capital Management reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,332 shares of the company’s stock after selling 90 shares during the period. Johnson & Johnson makes up 1.1% of Founders Capital Management’s portfolio, making the stock its 26th largest holding. Founders Capital Management’s holdings in Johnson & Johnson were worth $1,075,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Concentric Wealth Management LLC increased its stake in Johnson & Johnson by 3.2% in the 2nd quarter. Concentric Wealth Management LLC now owns 26,611 shares of the company’s stock worth $3,229,000 after purchasing an additional 813 shares in the last quarter. Vishria Bird Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $578,000. GW Henssler & Associates Ltd. lifted its holdings in shares of Johnson & Johnson by 1.1% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 119,457 shares of the company’s stock valued at $14,495,000 after buying an additional 1,276 shares during the last quarter. Hyman Charles D lifted its holdings in shares of Johnson & Johnson by 2.2% during the 2nd quarter. Hyman Charles D now owns 273,639 shares of the company’s stock valued at $33,203,000 after buying an additional 5,812 shares during the last quarter. Finally, Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson by 3.3% during the 2nd quarter. Brighton Jones LLC now owns 19,327 shares of the company’s stock valued at $2,345,000 after buying an additional 613 shares during the last quarter. 67.32% of the stock is owned by institutional investors and hedge funds.

NYSE JNJ traded down $1.00 during trading hours on Friday, hitting $137.52. 10,485,289 shares of the company traded hands, compared to its average volume of 6,120,494. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47. The stock has a market capitalization of $368.95 billion, a PE ratio of 16.81, a price-to-earnings-growth ratio of 2.38 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion during the quarter, compared to analysts’ expectations of $19.55 billion. Johnson & Johnson had a return on equity of 35.79% and a net margin of 17.99%. The business’s revenue was up .1% on a year-over-year basis. During the same period last year, the firm posted $2.06 earnings per share. As a group, research analysts forecast that Johnson & Johnson will post 8.6 EPS for the current year.

Several equities research analysts recently weighed in on JNJ shares. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 target price for the company in a report on Wednesday, March 27th. Morgan Stanley lifted their price target on Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Barclays reaffirmed an “equal weight” rating and issued a $135.00 price target (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Citigroup boosted their price objective on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research report on Monday, February 25th. Finally, BMO Capital Markets boosted their price objective on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $146.40.

TRADEMARK VIOLATION NOTICE: “Founders Capital Management Sells 90 Shares of Johnson & Johnson (JNJ)” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/johnson-johnson-jnj-shares-sold-by-founders-capital-management.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What is a Real Estate Investment Trust (REIT)?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.